



CLAUDIA J. FREHE, PH.D.

ASSOCIATE

Washington, D.C.

202.772.5378

cfrehe@atllp.com



Dr. Claudia Frehe has over a decade of life sciences patent prosecution experience, with particular depth in antibody therapeutics, gene-editing technologies (including CRISPR and RNA-editing platforms), RNA-based therapeutics, and cell and gene therapy. She draws on her scientific background in clinical immunology, immuno-oncology, and solid organ and stem cell transplantation to craft IP strategies that not only secure strong exclusivity but also support critical business milestones such as raising capital, preparing for an acquisition or IPO, or launching commercially.

By aligning patent strategy with business objectives, Claudia helps translate complex science into scalable, investor-facing assets that provide long-term value. As a patent attorney and previously as a patent agent, she has developed and managed worldwide patent portfolios, drafted and prosecuted patent applications across the life sciences, and is experienced in validity/invalidity, noninfringement, and freedom-to-operate analyses, due diligence, and coordinating worldwide prosecution with foreign associates.

Claudia received her Ph.D. from Baylor College of Medicine, where her research focused on developing and testing novel chimeric antigen receptor T cells targeting solid tumors. She subsequently completed a postdoctoral fellowship in at the National Cancer Institute within the Experimental Transplantation and Immunology Branch. Claudia also brings direct clinical experience to her practice, having earned certification as a clinical molecular biologist (ASCP) and worked at Houston Methodist Hospital, where she conducted pre- and post-operative HLA testing in support of solid organ and stem cell transplantation.

BACKGROUND

Prior to joining Armstrong Teasdale, Claudia was an associate at another D.C.-area law firm.

EDUCATION

- University of New Hampshire Franklin Pierce School of Law (J.D., 2025)
 - Certificate in Intellectual Property and Technology Law
- Baylor College of Medicine (Ph.D., 2014)
 - Translational Biology and Molecular Medicine
- University of Texas (2008)

SERVICES AND INDUSTRIES

Biotechnology
Emerging Companies
Intellectual Property
Intellectual Property Litigation
Patent
Agribusiness and Food
Health Care and Life Sciences

ADMISSIONS

District of Columbia
U.S. Patent and Trademark
Office

- Molecular Genetics
- University of Texas at Austin (B.A., B.S., 2006)
 - Neurobiology and Psychology

PROFESSIONAL ACTIVITIES

- Hispanic National Bar Association

LANGUAGES

- Spanish

THOUGHT LEADERSHIP

2021

Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7

Molecular Therapy

2021

Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains

Human Gene Therapy

2017

Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains

Molecular Therapy

2016

Chimeric Antigen Receptors for Cancer Immunotherapy

Tumor Immunology: Methods and Protocols

2016

Chondroitin Sulfate Proteoglycan 4 as a Target for Chimeric Antigen Receptor-based T-Cell Immunotherapy of Solid Tumors

Expert Opinion on Therapeutic Targets

2016

The Impact of Different Hinge and Transmembrane Components on the Function of a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor

Molecular Therapy

2016

Chimeric Antigen Receptor-redirected T cells Return to the Bench

Seminars in Immunology

2014

T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo

Clinical Cancer Research